Urispas and Multiple sclerosis relapse - a phase IV clinical study of FDA data

Summary:

Multiple sclerosis relapse is reported as a side effect among people who take Urispas (flavoxate hydrochloride), especially for people who are female, 50-59 old, also take Avonex, and have Multiple sclerosis.

The phase IV clinical study analyzes which people have Multiple sclerosis relapse when taking Urispas. It is created by eHealthMe based on reports of 590 people who have side effects when taking Urispas from the FDA, and is updated regularly.

What is Urispas?

Urispas has active ingredients of flavoxate hydrochloride. eHealthMe is studying from 598 Urispas users. Check the latest studies of Urispas.

What is Multiple sclerosis relapse?

Multiple sclerosis relapse (reoccurrence of a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath) is found to be associated with 1,033 drugs and 943 conditions by eHealthMe. Check the latest studies of Multiple sclerosis relapse.

On Jul, 24, 2026

590 people reported to have side effects when taking Urispas.
Among them, 18 people (3.05%) have Multiple sclerosis relapse.

Could Urispas cause Multiple sclerosis relapse?

Among these 18 people:

What is the gender of people who have Multiple sclerosis relapse when taking Urispas? *

female: 100 %
male: 0.0 %

What is the age of people who have Multiple sclerosis relapse when taking Urispas? *

What are other drugs people take besides Urispas? *

What are other side effects people have besides Multiple sclerosis relapse? *

Depression: 11 people, 61.11%
Progressive Multifocal Leukoencephalopathy (rapidly progressive neuromuscular disease caused by opportunistic infection of brain cells): 7 people, 38.89%
Pneumonia: 7 people, 38.89%
Urinary Tract Infection: 7 people, 38.89%
Sensory Disturbance (sense disturbance): 7 people, 38.89%
Acute Kidney Failure: 6 people, 33.33%
Muscle Spasms (muscle contraction): 5 people, 27.78%
Consciousness - Decreased: 5 people, 27.78%
Coronary Heart Disease (narrowing or blockage of the coronary arteries): 5 people, 27.78%
Sinusitis (inflammation of sinus): 5 people, 27.78%

What are the existing conditions these people have? *

Multiple Sclerosis (a nervous system disease that affects your brain and spinal cord. it damages the myelin sheath): 17 people, 94.44%
Pain: 3 people, 16.67%
Neuralgia (pain in one or more nerves): 3 people, 16.67%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 3 people, 16.67%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 3 people, 16.67%
Depression: 3 people, 16.67%
Bladder Disorder: 3 people, 16.67%
Urinary Tract Infection: 2 people, 11.11%
Relapsing-Remitting Multiple Sclerosis (reoccurrence of an inflammatory disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged): 1 person, 5.56%
Nausea (feeling of having an urge to vomit): 1 person, 5.56%

* Approximation only. Some reports may have incomplete information.

Do you take Urispas and have Multiple sclerosis relapse?

- Check whether Multiple sclerosis relapse is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Urispas:

Urispas (598 reports)

Browse all side effects of Urispas:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Multiple sclerosis relapse:

Multiple sclerosis relapse (1,033 drugs)

Browse all the conditions that are associated with Multiple sclerosis relapse:

Multiple sclerosis relapse (943 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on flavoxate hydrochloride (the active ingredients of Urispas) and Urispas (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.